

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-6. (Canceled)

7. (Previously presented) A full length infectious and genetically stable cDNA clone of Japanese encephalitis virus (JEV).

8. (Previously presented) The cDNA clone as set forth in claim 7, wherein the cDNA clone contains a promoter at the beginning of 5' end of a DNA sequence corresponding to a JEV genomic RNA and a restriction endonuclease recognition sequence at the end of 3' end of the DNA sequence as a runoff site.

9. (Previously presented) The cDNA clone as set forth in claim 8, wherein the promoter is SP6 or T7.

10. (Currently Amended) The cDNA clone as set forth in claim 8, wherein the restriction endonuclease recognition sequence [[is]] does not exist in the JEV genomic RNA.

11. (Previously presented) The cDNA clone as set forth in claim 8, wherein the restriction endonuclease recognition sequence is *XHo* I or *Xba* I.
12. (Previously Presented) The cDNA clone as set forth in claim 8, wherein the cDNA clone is selected from a group consisting of sequences represented by SEQ. ID. No 43 and No 44, and No 45, which all have SP6 promoter and sequences represented by SEQ. ID. No 46 and No 47, and No 48, which all have T7 promoter.
13. (Previously presented) A vector including the cDNA clone of claim 7.
14. (Previously presented) The vector as set forth in claim 13, wherein a bacterial artificial chromosome (BAC) is used for a parental vector.
15. (Previously Presented) The vector as set forth in claim 13, wherein the vector is selected from a group consisting of pBAC^{SP6}/JVFL/Xhol containing the JEV cDNA represented by SEQ. ID. No 43, pBAC^{SP6}/JVFLx/Xhol containing the JEV cDNA represented by SEQ. ID. No 44, pBAC^{SP6}/JVFLx/XbaI containing the JEV cDNA represented by SEQ. ID. No 45, pBAC^{T7}/JVFL/Xhol containing the JEV cDNA represented by SEQ. ID. No 46, pBAC^{T7}/JVFLx/Xhol containing the JEV cDNA represented by SEQ. ID. No 47, and pBAC^{T7}/JVFLx/XbaI containing the JEV cDNA represented by SEQ. ID. No 48.

16. (Currently Amended) The vector according to as set forth in claim 15, wherein the vector is pBAC^{T7}/JVFLx/XbaI having T7 promoter (Accession No : KCTC 10346BP).
17. (Previously Presented) The vector as set forth in claim 15, wherein the vector is pBAC^{SP6}/JVFLx/XbaI having SP6 promoter (Accession No : KCTC 10347BP).
18. (Previously presented) An infectious JEV RNA transcript synthesized from the cDNA clone of claim 7.
19. (Previously presented) The infectious JEV RNA transcript as set forth in claim 18, wherein virus-unrelated nucleotides at its 3' end are removed.
20. (Previously presented) The infectious JEV RNA transcript as set forth in claim 19, wherein the virus-unrelated nucleotides are removed by treating mung bean nuclease (MBN).
21. (Original) A cell transfected with the JEV RNA transcript of claim 18.
22. (Withdrawn) A synthetic JEV obtained by cultivation of the cell of claim 21.

23. (Withdrawn) A synthetic JEV as set forth in claim 22, wherein a mutation is introduced in the JEV cDNA.

24. (Withdrawn) A method for the expression of heterologous genes using the cDNA clone of claim 8 comprising the following steps:

- 1) preparing a recombinant JEV cDNA expression vector by inserting heterologous genes into the cDNA clone of claim 8;
- 2) producing a JEV RNA transcript from the above recombinant JEV cDNA expression vector;
- 3) preparing a cell transfected with the above JEV RNA transcript; and
- 4) expressing foreign proteins by culturing the above cell.

25. (Withdrawn) The method as set forth in claim 24, wherein the foreign genes are inserted at the beginning of the JEV 3'NTR of the JEV cDNA.

26. (Previously presented) A diagnostic reagent containing elements originated from the cDNA clone of claim 7.

27. (Currently Amended) An anti-JEV vaccine containing elements originated from the JEV cDNA clone of claim 7 ~~or the synthetic JEV of claim 22.~~

28. (Original) A therapeutic agent comprising the JEV cDNA of claim 7 as effective ingredients.

2[[8]]9. (Currently Amended) The cDNA clone as set forth in claim 8, wherein the JEV genomic RNA consists of a 5' nontranslated region (NTR), a single polypeptide coding region, and a 3' NTR.

30. (New) A full length infectious and genetically stable cDNA clone of Japanese encephalitis virus (JEV), comprising:

SEQ. ID. No 45 having SP6 promoter,
wherein the cDNA clone contains a promoter at the beginning of 5' end of a DNA sequence corresponding to a JEV genomic RNA and a restriction endonuclease recognition sequence at the end of 3' end of the DNA sequence as a runoff site.

31. (New) A vector, comprising:

a full length infectious and genetically stable cDNA clone of Japanese encephalitis virus (JEV),

wherein the vector is pBAC^{SP6}/JVFLx/XbaI.

32. (New) The vector according to claim 31, wherein the vector is pBAC^{SP6}/JVFLx/XbaI having SP6 promoter (Accession No: KCTC 10347BP).

33. (New) The vector according to claim 31, wherein the JEV comprises SEQ. ID. No 45.

34. (New) A full length infectious and genetically stable cDNA clone of Japanese encephalitis virus (JEV), comprising:

SEQ. ID. No 48 having T7 promoter,
wherein the cDNA clone contains a promoter at the beginning of 5' end of a DNA sequence corresponding to a JEV genomic RNA and a restriction endonuclease recognition sequence at the end of 3' end of the DNA sequence as a runoff site.

35. (New) A vector, comprising:

a full length infectious and genetically stable cDNA clone of Japanese encephalitis virus (JEV),
wherein the vector is pBAC^{T7}/JVFLx/XbaI.

36. (New) The vector according to claim 35, wherein the vector is pBAC^{T7}/JVFLx/XbaI having T7 promoter (Accession No : KCTC 10346BP).

37. (New) The vector according to claim 35, wherein the JEV comprises SEQ. ID. No 48.

38. (New) An anti-JEV vaccine containing elements originated from the synthetic JEV of claim 22.